34 results on '"Sun, C."'
Search Results
2. 558P Molecular subtyping endometrial carcinoma in Chinese population applying an NGS-based classifier and its association with prognosis
3. P-77 A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
4. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma
5. 1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)
6. 290P Treatment with tyrosine kinase inhibitors (TKIs) based therapy in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study
7. 1153P Classification of multifocal lung adenocarcinomas subtypes using next-generation sequencing in pN0M0 lung adenocarcinomas
8. P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
9. P-142 Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study
10. 1924P Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
11. 445P Tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A multicenter real-world study
12. 670P Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
13. 95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
14. 50P Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
15. 56P Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
16. 102P The genomic characteristics of JAK family in 11159 Chinese solid tumour patients
17. LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
18. Immune classification of soft tissue sarcoma predicts clinical outcome
19. NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
20. Immune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome
21. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis
22. A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial
23. 558P IL-1beta mediates anti-progression activities in renal cell carcinoma by inducing MCP-1
24. 59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening
25. IL-1b mediates anti-progression activities in renal cell carcinoma by inducing MCP-1
26. 1678PD - Immune classification of soft tissue sarcoma predicts clinical outcome
27. 987TiP - NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
28. 923TiP - A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial
29. 35P - IL-1b mediates anti-progression activities in renal cell carcinoma by inducing MCP-1
30. 1710P Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study.
31. 1700P Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial.
32. 872P Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study.
33. 78P First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors.
34. 112OImmune classification of soft tissue sarcoma and its association with molecular characteristics, and clinical outcome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.